Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors
 (+1) 509‑736-4000,  
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors
  1. RadioGel™
  2. Human Clinical Trials

Human Clinical Trials (coming in the future)

the next step in the evolution of RadioGel™ and Precision Radionuclide Therapy (PRnT)

Human Clinical Trials

We're actively engaged with the USA FDA on our Pre-Submission Investigational Device Exemption for RadioGel™. Once the completed application is finalized, and submited; upon approval we're planning to prepapre to treat Thyroid Cancer.


Updates Contact

Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB:RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Precision Radionuclide Therapy (PRnT)
  • US FDA IDE Process Updates
  • Human Clinical Trials
  • Scroll to top